Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 12/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.50 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.50 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30677276 | 0.89 | SRC (0.56) | SRCLMNAHTTHTR2AABL1 | |
| SCHEMBL3128302 | 0.88 | NPSR1 (0.55) | SRCLMNAPOLBHTR2A | |
| SCHEMBL3130094 | 0.86 | POLB (0.58) | SRCPOLBHTR2A | |
| SCHEMBL31748485 | 0.81 | SRC (0.47) | SRCLMNAHTR2AABL1EGFR | |
| SCHEMBL13303605 | 0.78 | SYK (0.61) | SRC | |
| SCHEMBL30677466 | 0.78 | ALDH1A1 (0.51) | SRCLMNAHTTPOLB | |
| SCHEMBL3120081 | 0.75 | CDK1 (0.43) | SRCLMNAHTR2A | |
| SCHEMBL12652535 | 0.75 | IGF1R (0.53) | SRCCHEK1IGF1R | |
| SCHEMBL30677407 | 0.75 | GAA (0.47) | SRCABL1EGFRERBB2MET | |
| SCHEMBL15243369 | 0.74 | CSNK1E (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204187-A1 | Purine Derivatives | PALAU PHARMA, S.A. (ES) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204187-A1 | Purine Derivatives | JAK3, JAK1, JAK2 | SRC 1007/4885LMNA 4233/4885HTT 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.